DES MOINES, Iowa, Oct. 2, 2024 /PRNewswire/ -- Ambetter Health, a product offered by a Centene Corporation (NYSE: CNC) company, which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace®, will now offer Iowans a variety of affordable health insurance plans to residents in 33 counties in Iowa in 2025. Open enrollment for the Health Insurance Marketplace for Iowa runs from Nov. 1, 2024, through Jan. 15, 2025. Enroll by Dec. 15 for coverage starting Jan. 1, 2025.
"With Ambetter Health, we've designed a variety of coverage options to help individuals access viable health solutions designed to meet their unique needs," said Mitch Wasden, Plan President & CEO of Iowa Total Care. "Our commitment is not just to provide high-quality insurance, but to build a healthier Iowa for all, where every member feels valued, supported and equipped to thrive."
Ambetter Health offers its members access to quality care, convenient services and valuable rewards. The 2025 benefits and offerings include:
Below is a full list of the counties in which Ambetter Health will be offered in 2025:
Iowa residents interested in learning more about Ambetter Health or enrolling in a health plan during the open enrollment period may visit ambetterhealth.com/en/ia.
About Ambetter Health
Ambetter Health serves under-insured and uninsured populations through the federal Health Insurance Marketplace. Ambetter Health is underwritten by Iowa Total Care, Inc., which is a Qualified Health Plan issuer in Iowa. For more information, please visit ambetterhealth.com/en/ia/. This is a solicitation for insurance. For information on your right to receive an Ambetter Health plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhealth.com/en/ and scroll to the bottom of the page.
Last Trade: | US$59.10 |
Daily Change: | 1.29 2.23 |
Daily Volume: | 4,074,504 |
Market Cap: | US$29.840B |
October 30, 2024 October 25, 2024 September 11, 2024 August 29, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB